| Ananworanich J, Clin Infect Dis, 2021 |
Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. |
| ARCHITECTS, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| Bhushan S, Int J Infect Dis, 2021 |
Efficacy and Safety of Pegylated Interferon-α2b in Moderate COVID-19: A phase 3, randomized, comparator-controlled, open-label study. |
| CORIMUNO-TOCI-2 (ICU), Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| COV-AID, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| COVIDOSE-2, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| COVIDSTORM, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| COVITOZ-01, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| Ehrmann S, Lancet Respir Med, 2021 |
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial |
| HMO-0224-20, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| IMMCOVA, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| Kosmopoulos A, iScience, 2021 |
A Randomized Trial of Icosapent Ethyl in Ambulatory Patients with COVID-19 |
| McCreary E, medrxiv, 2021 |
A Learning Health System Randomized Trial of Monoclonal Antibodies for Covid-19 |
| Moreira TG, Front Immunol, 2021 |
Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. |
| Rangon CM, Front Physiol, 2021 |
Auricular Neuromodulation for Mass Vagus Nerve Stimulation: Insights From SOS COVID-19 a Multicentric, Randomized, Controlled, Double-Blind French Pilot Study. |
| Reis G, medRxiv, 2021 |
EFFECT OF EARLY TREATMENT WITH FLUVOXAMINE ON RISK OF EMERGENCY CARE AND HOSPITALIZATION AMONG PATIENTS WITH COVID-19: THE TOGETHER RANDOMIZED PLATFORM CLINICAL TRIAL |
| REMDACTA, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
| Rodrigues C, Int J Antimicrob Agents, 2021 |
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. |
| Shinkai M, Infect Dis Ther, 2021 |
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. |
| TOCOVID, Unpublished, 2021 |
Results from Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 A Meta-analysis |
These interventions were not prioritized but they might be included in the future. Details here